All you need to know about DRDO's anti-Covid drug
- 3 years ago
With the country battling the second wave of Covid-19 infections, The Drugs Controller General of India (DCGI) on Saturday approved a drug developed by the DRDO for emergency use. The drug - 2-deoxy-D-glucose (2-DG) - has been approved as an adjunct therapy in moderate to severe cases of coronavirus.
According to the official statement, "clinical trial results have shown that this molecule helps in faster recovery of hospitalised patients and reduces supplemental oxygen dependence."
"Higher proportion of patients treated with 2-DG showed RT-PCR negative conversion in COVID patients. The drug will be of immense benefit to the people suffering from Covid-19," the statement goes on to say.
According to the official statement, "clinical trial results have shown that this molecule helps in faster recovery of hospitalised patients and reduces supplemental oxygen dependence."
"Higher proportion of patients treated with 2-DG showed RT-PCR negative conversion in COVID patients. The drug will be of immense benefit to the people suffering from Covid-19," the statement goes on to say.